Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06100627
Other study ID # AP301-PD-01
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date January 11, 2024
Est. completion date February 28, 2024

Study information

Verified date May 2024
Source Alebund Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, open-label, parallel-group, phase 1 study to evaluate the PD effect of AP301 capsule in healthy volunteers. The study is planned to have 4 treatment arms: Arm 1: 2.10 g/day; arm 2: 4.20 g/day; arm 3: 6.30 g/day; arm 4: 8.40 g/day.


Description:

A total of 32 participants will participate in this study and the study consists of 3 periods such as screening period, hospitalization period and follow up period.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date February 28, 2024
Est. primary completion date February 8, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 55 Years
Eligibility Important Inclusion Criteria: - Healthy male volunteers, 18-55 years of age - Body mass index (BMI) 18-30 kg/m2 (exclusive) at screening. Important Exclusion Criteria: - Serum phosphorus is below 1.00 mmol/L at screening. - History of significant gastrointestinal disease or disorder, major gastrointestinal surgeries, or cholecystectomy - History or symptoms of any clinically significant kidney, liver, broncho-pulmonary, gastrointestinal, neurological, psychiatric, cardiovascular, endocrine/metabolic, hematological diseases, or cancer. - History of specific allergies or allergic conditions or known allergies to the study drug as judged by the investigator, or any confirmed significant allergic reactions (urticaria or anaphylaxis) to any drug, or multiple drug allergies (non-active hay fever is acceptable). Allowing for childhood asthma, history of mild eczema that has had no flare ups for =5 years or is fully resolved. - Known history of allergy to common food like milk or gluten, or lactose intolerance, or special diet habit for religious/life-style reasons, which might potentially jeopardize the participant's compliance of study diet. - Any clinically significant concomitant disease, or condition or treatment that could interfere with the conduct of the study. - Confirmed (based on the average of 3 separate resting blood pressure measurements, after at least 5 minutes rest) systolic blood pressure (BP) greater than 150 or less than 90 mmHg, and diastolic BP greater than 90 or less than 50 mmHg at screening. - Clinically relevant ECG abnormalities on screening ECG. - Estimated glomerular filtration rate (eGFR) = 70 mL/min/1.73 m2. - Positive test at screening of any of the following: Hepatitis B (HBsAg), Hepatitis C (HCV Ab) or human immunodeficiency virus (HIV-1 or HIV-2 Ab). - Alanine aminotransferase (ALT) or aspartate transaminase (AST) > 1.5 × upper limit of normal (ULN), or any other clinically significant abnormalities in laboratory test results at screening. - Dosed with a small-molecule or biologic investigational drug within 30 days or 90 days, respectively, or 5 half-lives (whichever is the longer) prior to first dose of this study. - Positive urine test for drugs of abuse and/or positive alcohol test at screening. - Any medical or social conditions that, in the view of investigator, might potentially jeopardize the participant's compliance of study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AP301
Orally administered

Locations

Country Name City State
Australia Nucleus Network Pty Ltd Melbourne Victoria

Sponsors (1)

Lead Sponsor Collaborator
Alebund Pty Ltd

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Urinary phosphorus excretion during AP301 administration Average daily urinary phosphorus excretion during the 3 consecutive days of AP301 treatment From the Day 1 to Day 4 after dosing, assessed up to 3 days
Primary Effect of AP301 on urinary phosphorus excretion Change of average daily urinary phosphorus excretion from 3 days before treatment to 3 days during treatment. From Day -3 to Day 4 after dosing, assessed up to 6 days
Primary Urinary calcium excretion during AP301 administration Average daily urinary calcium excretion during the 3 consecutive days of AP301 treatment. From the Day 1 to Day 4 after dosing, assessed up to 3 days
Primary Effect of AP301 on urinary calcium excretion Change of average daily urinary calcium excretion from 3 days before treatment to 3 days during treatment. From Day -3 to Day 4 after dosing, assessed up to 6 days
Primary Effect of AP301 on serum phosphorus and calcium Changes of serum phosphorus and serum calcium from baseline to end of treatment. From Day -3 to Day 4 after dosing, assessed up to 6 days
Secondary Incidence and severity of adverse events (AEs) Number of participants with adverse events (AEs) and the intensity of adverse events.
Number of participants with serious adverse events (SAEs) and the intensity of adverse events.
From screening to hospitalization and follow up periods, assessed up to 43 days
Secondary Changes in clinical laboratory values Changes and their clinical meaningfulness in clinical laboratory values: Hematology, Biochemistry, Urinalysis From screening to hospitalization and follow up periods, assessed up to 43 days
Secondary Abnormal electrocardiogram (ECG) readings and their clinical meaningfulness ECG intervals (PR [PQ], QRS, QT, QTcF) and heart rate From screening to hospitalization and follow up periods, assessed up to 43 days
Secondary Changes of ECG parameters and their clinical meaningfulness ECG intervals (PR [PQ], QRS, QT, QTcF), heart rate, T-wave morphology and U-wave morphology. From screening to hospitalization and follow up periods, assessed up to 43 days
Secondary Abnormal vital signs and their clinical meaningfulness Blood pressure, heart rate and body temperature From screening to hospitalization and follow up periods, assessed up to 43 days
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1